Clinical trial · no report yet · Phase 2
IMCODE 003
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- NCT05968326 ↗
- Active, not recruiting
- Genentech, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Adenocarcinoma, Pancreatic Ductal
- Interventions
- Autogene cevumeran; Atezolizumab; mFOLFIRINOX
- Arms
- Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX · Experimental
- Arm 2: mFOLFIRINOX · Active comparator
- Enrollment
- 260 (estimated)
- Primary outcomes
- Disease Free Survival (DFS)
- Sponsor
- Genentech, Inc. with BioNTech SE
- Start
- Oct 18, 2023
- Primary completion
- Jan 1, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05968326 · updated Sep 9, 2026